Anish Patel Sells 17,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 17,500 shares of the stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $25.03, for a total value of $438,025.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total value of $90,675.00.
• On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.64, for a total value of $76,245.00.
• On Tuesday, February 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.11, for a total value of $73,661.25.
• On Monday, January 22nd, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.13, for a total value of $73,758.75.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $17.30 on Thursday. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00. The stock has a market cap of $712.76 million, a P/E ratio of -7.90 and a beta of 1.06. The stock has a 50 day simple moving average of $16.98 and a two-hundred day simple moving average of $14.31.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Enliven Therapeutics by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 1,230,888 shares of the company’s stock valued at $17,035,000 after buying an additional 79,071 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Enliven Therapeutics by 28.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 22,698 shares of the company’s stock worth $314,000 after purchasing an additional 5,008 shares in the last quarter. Barclays PLC increased its holdings in shares of Enliven Therapeutics by 208.7% in the 4th quarter. Barclays PLC now owns 42,078 shares of the company’s stock worth $583,000 after purchasing an additional 28,449 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Enliven Therapeutics by 1.8% in the 4th quarter. Citadel Advisors LLC now owns 2,394,448 shares of the company’s stock worth $33,139,000 after buying an additional 42,782 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Enliven Therapeutics by 69.8% in the 4th quarter. Royal Bank of Canada now owns 7,991 shares of the company’s stock worth $110,000 after buying an additional 3,284 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.